Английская Википедия:Dacomitinib
Шаблон:Short description Шаблон:Use dmy dates Шаблон:Infobox drug
Dacomitinib, sold under the brand name Vizimpro, is a medication for the treatment of non-small-cell lung carcinoma (NSCLC). It is a selective and irreversible inhibitor of EGFR.[1]
Dacomitinib has advanced to several Phase III clinical trials.Шаблон:When The January 2014 results of the first trials were disappointing, with a failure to meet the study goals.[2][3][4] Additional Phase III trials are ongoingШаблон:When.[2]
In 2017, results of a trial comparing dacomitinib to gefitinib for NSCLC (driven by mutated EGFR) were announced.[5]
Dacomitinib was approved for medical use in the United States in September 2018,[6] in Japan in 2019, and in the European Union in 2019,[7] for the treatment of non-small cell lung cancer with epidermal growth factor receptor (EGFR) gene mutation.
References
External links
Шаблон:Targeted cancer therapeutic agents Шаблон:Growth factor receptor modulators Шаблон:Portal bar
Шаблон:Antineoplastic-drug-stub
